NASDAQ:GHSI

Guardion Health Sciences Competitors

$1.86
-0.26 (-12.26 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.83
Now: $1.86
$2.07
50-Day Range
$0.50
MA: $2.67
$6.54
52-Week Range
$0.99
Now: $1.86
$8.40
Volume1.35 million shs
Average Volume4.52 million shs
Market Capitalization$45.43 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72

Competitors

Guardion Health Sciences (NASDAQ:GHSI) Vs. ETON, ENLV, LTRN, HROW, HTBX, and DMAC

Should you be buying GHSI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Guardion Health Sciences, including Eton Pharmaceuticals (ETON), Enlivex Therapeutics (ENLV), Lantern Pharma (LTRN), Harrow Health (HROW), Heat Biologics (HTBX), and DiaMedica Therapeutics (DMAC).

Guardion Health Sciences (NASDAQ:GHSI) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

5.3% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 29.1% of Eton Pharmaceuticals shares are held by institutional investors. 3.9% of Guardion Health Sciences shares are held by insiders. Comparatively, 12.9% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Guardion Health Sciences and Eton Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardion Health Sciences-480.23%-75.36%-68.15%
Eton PharmaceuticalsN/A-310.64%-152.51%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Guardion Health Sciences and Eton Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardion Health Sciences0000N/A
Eton Pharmaceuticals00203.00

Eton Pharmaceuticals has a consensus price target of $12.00, indicating a potential upside of 62.16%. Given Eton Pharmaceuticals' higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Guardion Health Sciences.

Risk & Volatility

Guardion Health Sciences has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Earnings and Valuation

This table compares Guardion Health Sciences and Eton Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardion Health Sciences$900,000.0050.48$-10,880,000.00N/AN/A
Eton Pharmaceuticals$460,000.00392.65$-18,320,000.00($1.03)-7.18

Guardion Health Sciences has higher revenue and earnings than Eton Pharmaceuticals.

Summary

Eton Pharmaceuticals beats Guardion Health Sciences on 7 of the 11 factors compared between the two stocks.

Guardion Health Sciences (NASDAQ:GHSI) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

5.3% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 2.4% of Enlivex Therapeutics shares are held by institutional investors. 3.9% of Guardion Health Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Guardion Health Sciences and Enlivex Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardion Health Sciences-480.23%-75.36%-68.15%
Enlivex TherapeuticsN/A-34.60%-28.47%

Analyst Ratings

This is a breakdown of recent recommendations for Guardion Health Sciences and Enlivex Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardion Health Sciences0000N/A
Enlivex Therapeutics00103.00

Enlivex Therapeutics has a consensus target price of $33.00, indicating a potential upside of 189.22%. Given Enlivex Therapeutics' higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Guardion Health Sciences.

Risk & Volatility

Guardion Health Sciences has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Guardion Health Sciences and Enlivex Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardion Health Sciences$900,000.0050.48$-10,880,000.00N/AN/A
Enlivex TherapeuticsN/AN/A$-9,380,000.00($1.11)-10.28

Enlivex Therapeutics has lower revenue, but higher earnings than Guardion Health Sciences.

Summary

Enlivex Therapeutics beats Guardion Health Sciences on 7 of the 10 factors compared between the two stocks.

Guardion Health Sciences (NASDAQ:GHSI) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

5.3% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 2.6% of Lantern Pharma shares are held by institutional investors. 3.9% of Guardion Health Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Guardion Health Sciences and Lantern Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardion Health Sciences-480.23%-75.36%-68.15%
Lantern PharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Guardion Health Sciences and Lantern Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardion Health Sciences0000N/A
Lantern Pharma02002.00

Lantern Pharma has a consensus target price of $24.50, indicating a potential upside of 52.27%. Given Lantern Pharma's higher probable upside, analysts plainly believe Lantern Pharma is more favorable than Guardion Health Sciences.

Earnings & Valuation

This table compares Guardion Health Sciences and Lantern Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardion Health Sciences$900,000.0050.48$-10,880,000.00N/AN/A
Lantern PharmaN/AN/AN/AN/AN/A

Lantern Pharma has lower revenue, but higher earnings than Guardion Health Sciences.

Summary

Lantern Pharma beats Guardion Health Sciences on 4 of the 7 factors compared between the two stocks.

Guardion Health Sciences (NASDAQ:GHSI) and Harrow Health (NASDAQ:HROW) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

5.3% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 44.4% of Harrow Health shares are held by institutional investors. 3.9% of Guardion Health Sciences shares are held by insiders. Comparatively, 12.4% of Harrow Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Guardion Health Sciences and Harrow Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardion Health Sciences-480.23%-75.36%-68.15%
Harrow Health-3.94%-3.52%-1.36%

Analyst Ratings

This is a breakdown of recent recommendations for Guardion Health Sciences and Harrow Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardion Health Sciences0000N/A
Harrow Health00103.00

Harrow Health has a consensus target price of $14.00, indicating a potential upside of 103.49%. Given Harrow Health's higher probable upside, analysts plainly believe Harrow Health is more favorable than Guardion Health Sciences.

Risk & Volatility

Guardion Health Sciences has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Harrow Health has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Earnings & Valuation

This table compares Guardion Health Sciences and Harrow Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardion Health Sciences$900,000.0050.48$-10,880,000.00N/AN/A
Harrow Health$51.17 million3.49$170,000.00($0.29)-23.72

Harrow Health has higher revenue and earnings than Guardion Health Sciences.

Summary

Harrow Health beats Guardion Health Sciences on 10 of the 11 factors compared between the two stocks.

Guardion Health Sciences (NASDAQ:GHSI) and Heat Biologics (NASDAQ:HTBX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

5.3% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 49.8% of Heat Biologics shares are held by institutional investors. 3.9% of Guardion Health Sciences shares are held by insiders. Comparatively, 5.5% of Heat Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Guardion Health Sciences and Heat Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardion Health Sciences-480.23%-75.36%-68.15%
Heat Biologics-527.90%-44.07%-36.38%

Analyst Ratings

This is a breakdown of recent recommendations for Guardion Health Sciences and Heat Biologics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardion Health Sciences0000N/A
Heat Biologics00403.00

Heat Biologics has a consensus target price of $20.00, indicating a potential upside of 189.02%. Given Heat Biologics' higher probable upside, analysts plainly believe Heat Biologics is more favorable than Guardion Health Sciences.

Risk & Volatility

Guardion Health Sciences has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Heat Biologics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500.

Earnings & Valuation

This table compares Guardion Health Sciences and Heat Biologics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardion Health Sciences$900,000.0050.48$-10,880,000.00N/AN/A
Heat Biologics$3.05 million57.65$-20,020,000.00N/AN/A

Guardion Health Sciences has higher earnings, but lower revenue than Heat Biologics.

Summary

Heat Biologics beats Guardion Health Sciences on 8 of the 11 factors compared between the two stocks.

Guardion Health Sciences (NASDAQ:GHSI) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Guardion Health Sciences and DiaMedica Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardion Health Sciences0000N/A
DiaMedica Therapeutics00603.00

DiaMedica Therapeutics has a consensus target price of $23.8333, indicating a potential upside of 154.90%. Given DiaMedica Therapeutics' higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Guardion Health Sciences.

Earnings & Valuation

This table compares Guardion Health Sciences and DiaMedica Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardion Health Sciences$900,000.0050.48$-10,880,000.00N/AN/A
DiaMedica Therapeutics$500,000.00351.11$-10,650,000.00N/AN/A

DiaMedica Therapeutics has lower revenue, but higher earnings than Guardion Health Sciences.

Profitability

This table compares Guardion Health Sciences and DiaMedica Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardion Health Sciences-480.23%-75.36%-68.15%
DiaMedica TherapeuticsN/A-68.28%-62.90%

Insider and Institutional Ownership

5.3% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 35.8% of DiaMedica Therapeutics shares are held by institutional investors. 3.9% of Guardion Health Sciences shares are held by insiders. Comparatively, 12.6% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Guardion Health Sciences has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500.

Summary

DiaMedica Therapeutics beats Guardion Health Sciences on 10 of the 11 factors compared between the two stocks.


Guardion Health Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.3$7.40-1.4%$180.62 million$460,000.00-6.22Insider Selling
Enlivex Therapeutics logo
ENLV
Enlivex Therapeutics
1.4$11.41-2.7%$179.82 millionN/A-15.42Decrease in Short Interest
Lantern Pharma logo
LTRN
Lantern Pharma
1.2$16.09-6.3%$179.73 millionN/A0.00Increase in Short Interest
Harrow Health logo
HROW
Harrow Health
1.4$6.88-2.5%$178.76 million$51.17 million-86.00
Heat Biologics logo
HTBX
Heat Biologics
1.6$6.92-7.2%$175.84 million$3.05 million0.00News Coverage
DiaMedica Therapeutics logo
DMAC
DiaMedica Therapeutics
1.3$9.35-6.0%$175.56 million$500,000.00-12.30News Coverage
scPharmaceuticals logo
SCPH
scPharmaceuticals
1.3$6.40-1.7%$175.07 millionN/A-3.95
OncoSec Medical logo
ONCS
OncoSec Medical
1.6$4.63-11.7%$172.05 millionN/A-1.88
AVEO Pharmaceuticals logo
AVEO
AVEO Pharmaceuticals
1.2$6.31-8.1%$171.19 million$28.80 million-4.07Decrease in Short Interest
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.26-2.3%$170.65 million$15.96 million-2.58
Agile Therapeutics logo
AGRX
Agile Therapeutics
1.9$1.94-1.5%$170 millionN/A-3.88
Oncolytics Biotech logo
ONCY
Oncolytics Biotech
1.2$3.26-23.0%$169.79 millionN/A-4.02
Exicure logo
XCUR
Exicure
1.5$1.93-5.2%$169.76 million$1.30 million-7.42
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.5$0.72-13.9%$169.67 million$2.18 million-0.48Gap Up
SCYNEXIS logo
SCYX
SCYNEXIS
1.4$8.21-2.7%$169.32 million$120,000.00-2.21Analyst Report
Zynerba Pharmaceuticals logo
ZYNE
Zynerba Pharmaceuticals
1.3$4.06-5.4%$167.48 million$90,000.00-2.19Decrease in Short Interest
Strongbridge Biopharma logo
SBBP
Strongbridge Biopharma
1.5$2.47-6.5%$166.84 million$21.71 million-2.71Increase in Short Interest
Marker Therapeutics logo
MRKR
Marker Therapeutics
1.5$2.07-2.9%$164.16 million$210,000.00-3.76
ObsEva logo
OBSV
ObsEva
1.4$2.85-6.7%$164.03 millionN/A-1.14Decrease in Short Interest
News Coverage
Gap Down
Calithera Biosciences logo
CALA
Calithera Biosciences
1.8$2.23-5.4%$163.50 million$22.25 million-1.62
Chiasma logo
CHMA
Chiasma
1.7$2.82-6.7%$163.12 millionN/A-1.94
Satsuma Pharmaceuticals logo
STSA
Satsuma Pharmaceuticals
1.5$5.14-2.7%$162.02 millionN/A-1.95
Clearside Biomedical logo
CLSD
Clearside Biomedical
1.3$2.79-4.7%$160.21 million$2.17 million-8.72
InflaRx logo
IFRX
InflaRx
1.4$3.70-1.1%$159.94 millionN/A-2.26
Milestone Pharmaceuticals logo
MIST
Milestone Pharmaceuticals
1.4$5.35-5.2%$159.68 millionN/A-2.28
AcelRx Pharmaceuticals logo
ACRX
AcelRx Pharmaceuticals
1.3$1.34-4.5%$159.39 million$2.29 million-2.39Increase in Short Interest
Processa Pharmaceuticals logo
PCSA
Processa Pharmaceuticals
1.2$10.23-3.9%$158.79 millionN/A0.00Gap Down
Catalyst Biosciences logo
CBIO
Catalyst Biosciences
1.5$5.05-1.2%$158.22 million$10,000.00-1.58Increase in Short Interest
News Coverage
ContraFect logo
CFRX
ContraFect
1.4$4.02-4.2%$158.12 millionN/A-1.51Increase in Short Interest
Analyst Revision
Biofrontera logo
BFRA
Biofrontera
1.2$5.49-2.0%$155.69 million$35.02 million-7.13Increase in Short Interest
News Coverage
Abeona Therapeutics logo
ABEO
Abeona Therapeutics
1.6$1.55-5.8%$153.12 million$3 million-1.49
Galecto logo
GLTO
Galecto
1.7$6.00-4.7%$151.57 millionN/A0.00High Trading Volume
Aquestive Therapeutics logo
AQST
Aquestive Therapeutics
1.7$4.34-7.8%$150.03 million$52.61 million-2.84
Concert Pharmaceuticals logo
CNCE
Concert Pharmaceuticals
1.7$4.54-0.7%$146.07 million$1.08 million-1.77
NeuBase Therapeutics logo
NBSE
NeuBase Therapeutics
1.3$6.15-5.7%$142.56 millionN/A-6.83
Evofem Biosciences logo
EVFM
Evofem Biosciences
1.5$1.69-3.6%$140.48 millionN/A-0.87
Enochian Biosciences logo
ENOB
Enochian Biosciences
0.5$2.94-4.4%$140.42 millionN/A0.00Increase in Short Interest
Adamas Pharmaceuticals logo
ADMS
Adamas Pharmaceuticals
1.5$4.52-0.0%$138.17 million$54.64 million-2.05
Eyenovia logo
EYEN
Eyenovia
1.6$5.36-7.3%$137.35 millionN/A-4.87
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.3$1.83-0.5%$137.17 millionN/A0.00Increase in Short Interest
News Coverage
Odonate Therapeutics logo
ODT
Odonate Therapeutics
1.8$3.52-9.4%$135.89 millionN/A-0.90Analyst Upgrade
Decrease in Short Interest
GlycoMimetics logo
GLYC
GlycoMimetics
1.7$2.59-11.6%$133.49 millionN/A-2.29High Trading Volume
Hepion Pharmaceuticals logo
HEPA
Hepion Pharmaceuticals
1.1$1.74-6.3%$132.63 millionN/A-0.29Increase in Short Interest
Liminal BioSciences logo
LMNL
Liminal BioSciences
1.1$4.42-7.0%$132.35 million$3.70 million-1.50
Synlogic logo
SYBX
Synlogic
1.6$3.30-0.9%$130.87 million$2.22 million-2.02
Lipocine logo
LPCN
Lipocine
1.4$1.47-4.8%$129.79 million$170,000.00-3.34
Galectin Therapeutics logo
GALT
Galectin Therapeutics
1.4$2.27-15.4%$129.74 millionN/A-5.82
IMARA logo
IMRA
IMARA
1.4$7.29-5.2%$128.12 millionN/A0.00
LifeVantage logo
LFVN
LifeVantage
1.0$9.03-0.0%$127.93 million$232.91 million10.75Decrease in Short Interest
Orgenesis logo
ORGS
Orgenesis
0.3$5.22-2.1%$127.43 million$33.26 million1.12
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.